#United States #San Francisco #Nektar Therapeutics #Alopecia Areata #Rezpegaldesleukin

Nektar Therapeutics to Present Key Findings from REZOLVE-AA Phase 2b Study

Nektar Therapeutics, a clinical-stage biotechnology firm, has announced it will hold a conference call on December 16, 2025, at 8:00 AM ET / 5:00 AM PT. This session will be dedicated to discussing the topline results from the 36-week induction treatment phase of their ongoing Phase 2b study, REZOLVE-AA, which investigates the efficacy of rezpegaldesleukin in treating severe to very severe alopecia areata.

The study aims at assessing the potential of rezpegaldesleukin, a regulatory T-cell proliferator, to alter the disease course in patients suffering from alopecia areata, an autoimmune condition that often results in hair loss. Alopecia areata can have a significant psychological burden on affected individuals, making effective treatment options crucial.

The results of this conference will be shared in a morning press release, which will also serve as an introduction to the subsequent live webcast. Investors and the public can access the webcast through a link provided by Nektar. All materials from the event, including the slides and the related press release, will be made available in the events section of Nektar's website. Moreover, a replay of the conference will be accessible for at least 30 days following the live event, ensuring that stakeholders can review the findings at their convenience.

About Nektar Therapeutics

Nektar Therapeutics is at the forefront of developing innovative therapies that target underlying immunological dysfunctions associated with autoimmune disorders and chronic inflammatory conditions. Their flagship candidate, rezpegaldesleukin (also presented as NKTR-358), is not only under evaluation for alopecia areata but also in clinical trials aimed at treating atopic dermatitis and Type 1 diabetes mellitus.

In addition to rezpegaldesleukin, Nektar's diverse pipeline comprises advanced therapeutic approaches, including a preclinical bispecific antibody targeting tumor necrosis factor receptor type II (TNFR2). Their strategic collaborations extend to the investigational agent NKTR-255, an IL-15 receptor agonist, designed to enhance the immune system’s ability to combat cancers.

Nektar Therapeutics proudly operates from its headquarters in San Francisco, California. Dedicated to pushing the boundaries of modern medicine, Nektar places a strong emphasis on advancing treatments that can significantly improve quality of life for individuals with serious medical conditions. Those interested in staying updated about Nektar's journey and innovations can explore more on their website or through LinkedIn.

All interested participants are encouraged to join the conference call on December 16 to gain insights into these promising treatments for alopecia areata. Access to the live webcast will be provided on Nektar's official platform.

Conclusion

The upcoming conference by Nektar Therapeutics promises to shed light on important advancements in the treatment of alopecia areata with the results from the REZOLVE-AA Phase 2b study. As the biotechnology landscape evolves, updates such as these highlight the continuous efforts by companies like Nektar to address the challenges faced by patients living with autoimmune diseases.

For further inquiries or information regarding the event, please reach out to the press contacts listed in the official Nektar Therapeutics announcement.